Paper Details

  1. Home
  2. Paper Details

The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance.

Author: AbdelmalakMary, AhmedMyra, AnwerMohammed, AshtonAnthony W, DuYanming, IvanchenkoPavel, JiaoXuanmao, PestellRichard, RandhawaAmritdeep, SinghRajanbir

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Cyclin-dependent kinase inhibitors (CDKIs) are used to treat breast cancer, but resistance can occur. This review discusses the different CDKIs, their effectiveness, and potential new therapies to enhance their efficacy. There is a need for a deeper understanding of cyclin/CDK function and the impact of CDKIs on the immune response.
Paper Details　
Original Abstract of the Article :
Cyclin-dependent kinases (CDKs) govern cell-cycle checkpoint transitions necessary for cancer cell proliferation. Recent developments have illustrated nuanced important differences between mono CDK inhibitor (CDKI) treatment and the combination therapies of breast cancers. The CDKIs that are current...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9655989/

データ提供：米国国立医学図書館（NLM）

CDK Inhibitors in Breast Cancer: A Renaissance of Hope

Breast cancer, a condition that affects millions of women worldwide, can feel like a vast desert landscape, where treatments and challenges can seem endless. This research delves into the world of cyclin-dependent kinase inhibitors (CDKIs), a class of drugs that show promise in combating breast cancer.

A New Era of CDKI Therapy

This research focuses on the use of CDKIs in breast cancer treatment, particularly those that target CDK4 and CDK6, which are involved in cell cycle regulation. It highlights the efficacy of these drugs, especially when combined with endocrine therapy.

Challenges and Opportunities

The research acknowledges the challenges associated with CDKI therapy, including resistance and side effects. It also points to the ongoing development of new therapies to enhance CDKI effectiveness and address the issue of drug resistance.

Dr.Camel's Conclusion

This research offers a promising glimpse into the future of breast cancer treatment, highlighting the renaissance of CDKI therapy. It underscores the importance of continued research to optimize these therapies, address resistance, and improve the overall treatment experience for breast cancer patients.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-11-17
Further Info :

Pubmed ID

36358806

DOI: Digital Object Identifier

PMC9655989

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.